GlassScriptPhysician profile
Jungah Seo
NPI 1144973132
$6,581.30
in general payments reported to CMS, 2019-2025
35 companies · $1,109 in 2025
The $1,109 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,165 · 2023: $2,045 · 2024: $2,262 · 2025: $1,109.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,416.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,416.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,174.63 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,047.50 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $783.18 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $448.29 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Gilead Sciences, INC. | $438.97 | 2023-2025 | Vemlidy |
| Bayer Healthcare Pharmaceuticals INC. | $376.25 | 2023-2025 | |
| Radius Health, INC. | $286.62 | 2023-2025 | Tymlos |
| Medtronic, INC. | $238.89 | 2023-2025 | Intellis Adaptivestim, Interstim |
| Sanofi-Aventis U.S. LLC | $194.16 | 2022-2023 | |
| Astellas Pharma US INC | $190.48 | 2024-2025 | Veozah |
| Glaxosmithkline, LLC. | $185.40 | 2023-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Amarin Pharma, INC. | $166.37 | 2022 | |
| Amgen INC. | $164.62 | 2022-2025 | Otezla, Repatha, Prolia |
| Dexcom, INC. | $138.39 | 2022-2025 | Dexcom G6 Transmitter |
| Scilex Pharmaceuticals INC. | $80.04 | 2023-2025 | Ztlido |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $77.05 | 2024 | Korlym |
| Aimmune Therapeutics, INC. | $59.49 | 2024-2025 | Zenpep |
| Vbi Vaccine (Delaware) INC. | $59.20 | 2023 | Prehevbrio |
| Exact Sciences Corporation | $50.63 | 2023-2024 | Cologuard Collection Kit |
| Corium, LLC | $49.99 | 2023 | Adlarity |
| Pfizer INC. | $49.95 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.69 | 2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.93 | 2024 | |
| Scpharmaceuticals INC. | $30.71 | 2024 | |
| Vertex Pharmaceuticals Incorporated | $27.38 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $24.17 | 2023 | Rexulti |
| Vivus LLC | $21.10 | 2023 | Qsymia |
| Sumitomo Pharma America, INC. | $20.00 | 2025 | Gemtesa |
| Sanofi Pasteur INC. | $19.45 | 2023 | |
| Ars Pharmaceuticals Operations, INC. | $19.40 | 2025 | Neffy |
| Ardelyx, INC. | $18.25 | 2024 | Ibsrela |
| Insulet Corporation | $15.09 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $14.31 | 2025 | Zoryve |
| Nestle Healthcare Nutrition INC. | $14.16 | 2023 | |
| Idorsia Pharmaceuticals US INC | $13.56 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jungah Seo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.